Navigation Links
NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension
Date:7/24/2008

SOPHIA ANTIPOLIS, France, July 24 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced the top-line results from the 52-week open label safety extension that was conducted following the completion of the 301 phase 3 study for naproxcinod. The results revealed no unexpected safety findings and efficacy was maintained for the one-year duration of the study, as measured by the patients' global assessment scale. In addition, the results showed that the patients' mean blood pressure was stable for 52 weeks following the completion of the 301 study, suggesting that naproxcinod does not increase blood pressure over time. Naproxcinod is NicOx' lead investigational drug and the first compound in the Cyclooxygenase-Inhibiting Nitric Oxide Donator (CINOD) class, which NicOx is developing for the treatment of the signs and symptoms of osteoarthritis.

The 301 safety extension study was conducted in 92 clinical centers in the United States and enrolled the first 500 eligible patients with osteoarthritis of the knee who successfully completed the 301 phase 3 study for naproxcinod (see press releases of June 13, 2008 and November 12, 2007). NicOx expects to announce the top-line efficacy results from the ongoing 302 and 303 pivotal phase 3 studies for naproxcinod in the second half of 2008, ahead of a projected New Drug Application (NDA) in mid-2009.

Pascal Pfister MD, Chief Scientific Officer and Head of Research and Development at NicOx, said: "The data from this open label trial form an important part of our long term safety database for naproxcinod. We are happy with the good overall safety we have observed in this study and look forward to gaining further 52 week data from the 302 study, which includes an active control arm."

The 302 study is being conducted in patients with osteoarthritis of the knee and efficacy is being measured at 13 weeks by the same three co-primary endpoints as in the 301 and 303 studies. In addition, th
'/>"/>

SOURCE NicOx
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. NicOx Completes Enrollment of Two Ambulatory Blood Pressure Measurement (ABPM) Studies for Naproxcinod in Hypertensive OA Patients
2. NicOx Announces Blood Pressure Analysis From 301 Phase 3 Study for Naproxcinod at EULAR
3. NicOx Completes Patient Enrollment in Third Naproxcinod Pivotal Phase 3 Study
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs
6. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
7. NicOx Completes Enrollment in Second Pivotal Phase 3 Study for Naproxcinod and Provides Development Update
8. NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020
9. NicOx Naproxcinod Phase 3 Results Presented at American College of Rheumatology
10. NicOx Naproxcinod ABPM Data Presented at American Heart Association
11. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)..., , WHITEHOUSE STATION, N.J., Dec. 1 /PRN...that the U.S. Food and Drug Administration (FDA) h...um bicarbonate 1100 mg capsules), for over-the-cou... will be marketed over-the-counter by Schering-Plo...care division of Merck & Co., Inc. Schering-Pl...
(Date:12/1/2009)..., , NEW YORK, Dec. 1 ...rch report is available in its catalogue: ,, T...sts to 2015, Competitive Benchmarking, Product Pip...linker.com/p0166817/The-Future-of-Oncology-Therape...marking-Product-Pipeline-and-Deals-Analysis.html ...
(Date:12/1/2009)..., , NEWNAN, Ga., Dec. 1 /PRNewswire/...ialty surface treatments for medical devices and o...nt and Chief Executive Officer, Thomas A. Gordy, w...ade at the Innovations in Cardiovascular Intervent...ve the era of petty self-interest behind and focus...
Breaking Medicine Technology:FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 2FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 3FDA Approves ZEGERID OTC(TM) for Over-the-Counter Treatment of Frequent Heartburn 4Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 2Reportlinker Adds The Future of Oncology Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis 3CeloNova BioSciences CEO Urges More Heart, More Passion, More Honesty, and All Urgency in Developing Medical Devices 2Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 1Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 2Dr Susan Blumenthal Meridian International Centers Global Health Chair Named Health Leader of the Year 49759 3Marking anorexia with a brain protein 49756 1Medical Study Establishes First Ever Long Term Benefits for Macular Degeneration Sufferers Using Macular Health Vitamin Supplement 49755 1
...ta on Newly-Approved Cimzia(R) Presented at Digest...nounced today that data,presented at Digestive Dis...cacy and safety of Cimzia(R) (certolizumab pegol) ... to severe Crohn,s disease. Data also showed,conti...and the remission,rate remained stable in many of ...
... Clinical trial data for Perforomist(TM) (Formoter... at International ATS Conference --, NAPA, Calif....l Conference of the American Thoracic Society (ATS...omist(TM) Inhalation Solution,(formoterol fumarate...tion,and Spiriva(R) (tiotropium; TIO) is significa...
Other Medicine Technology:Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 2Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 3Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 4Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 5Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 6Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 7Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohn's Disease 8Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 2Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 3Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 4Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 5Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone 6
(Date:12/1/2009)...GTON, Dec. 1 With employ...g number of employers are providing self-service d...ment season, according to a new survey by Watson W... of employers who offer these tools believe they l...ons. ,, According to the survey, 45 percent of ...
(Date:12/1/2009)...BANK, N.J., Dec. 1 A national surv...ing is ideal for their babies and themselves but a...s best for them and their families. ,, See vide...FC_37156/ ,, The survey of mothers of children...s (83%) made their infant feeding decision prior t...
(Date:12/1/2009)...ELD, Mich., Dec. 1 Firs...First Mercury" or the "Company") announced today t...clared a quarterly cash dividend of $0.025 per sha...f record at the close of business on December 15, ...ration ,, First Mercury Financial Corporation ...
(Date:12/1/2009)...e who would benefit from liver surgery after chemo...lthDay News) -- A CT scan of liver tumors caused b... overall survival after chemotherapy, researchers ...oxic chemotherapy has been shown to improve surviv...nd to produce better results in patients having su...
(Date:12/1/2009)...cember 1, 2009) Wistar Institute researchers and ...and New York University have identified immune sys...e lung tumors in people at high risk for developin...mber 1 in Cancer Research , a journal of the Amer...o a simple blood test to detect lung cancer in its...
Breaking Medicine News(10 mins):Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3Health News:VIDEO from Medialink and HealthyWomen: Breast, Bottle or Both? 2Health News:CT Scan May Predict Colon Cancer Survival 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3
... does not have a precise figure of those wounded i... The death toll is relatively easy to keep track o...the wounded estimates vary, between 35,000 and 53,...ns all round. More than 800 of them have lost...
...e from Kerala and the other from Bangalore -- are ...stainable Energy. Saji Das from Biotech i...curity Award (30,000 pounds) for developing and in...of the judging panel: "The judges were highly impr...
...n's tribal areas still consider home to be the saf...raceptives and don't get their children immunised.... that works in tribal regions of Udaipur district,...omen in the region. According to the findings, aro...
...e University professors, Volodymyr Tarabara and To...y the worlds waters . Tarabara and Voice ar...ental engineers and scientists from two U.S. resea... With the biggest funding of its kind a $2.5 m...
...ten singer Kerry Katonas drug dealer has revealed ...Brian McFadden . The singer and McFadden Ki...er custody of their two daughters Molly, 4, and L... "Kerry cares more about drugs than anything in ...
...e University of California, San Diego (UCSD) Skagg...ave patented a strategy for developing a human vac...MV) infection and disease. CMV, a type of ...y doesnt protect against infection by the virus, e...
Other Medicine News:Health News:US Trying Hard to Provide Proper Treatment for Wounded Soldiers 2Health News:US Trying Hard to Provide Proper Treatment for Wounded Soldiers 3Health News:US Trying Hard to Provide Proper Treatment for Wounded Soldiers 4Health News:Indian Projects Win Top Ashden Awards 2Health News:Poor Health Practices Plague Rajasthan Tribal Women 2Health News:Two MSU Professors Spearhead International Water Project 2Health News:Two MSU Professors Spearhead International Water Project 3Health News:Drugs More Important Than Kids for Katona, Says Her Candy Man 2Health News:Human Vaccine for Herpes Virus on the Anvil 2Health News:Human Vaccine for Herpes Virus on the Anvil 3
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: